Skip to content
New: free dose calculator with 14 peptide presets. No signup.
Peptides Academy

Immune Support Peptide Stack

A combination approach targeting immune function through three complementary mechanisms: adaptive immune restoration (Thymosin Alpha-1), innate antimicrobial defense (LL-37), and mucosal immune modulation (KPV). This stack addresses both immune surveillance and inflammatory regulation — calibrating rather than blindly boosting immune response.

Quick Comparison

PropertypeptideImmune Support Stack
SourceSalmon DNA fragmentsVarious sources
Primary MechanismA2A receptor activation, DNA repairVaries by ingredient
Key BenefitsTissue regeneration, anti-inflammation, collagen boostMultiple skin benefits
Best Time to ApplyAM or PMAM or PM
Can Combine?Generally compatible — check specific guidelines.

How to Use Together

The three peptides target different arms of the immune system and can be administered in parallel:

**Thymosin Alpha-1**: 1.6 mg subcutaneous injection, 2× per week. This is the approved dosing schedule (Zadaxin) for immune modulation. Cycles of 8–12 weeks with 4-week breaks. This is the backbone of the stack — the peptide with the deepest clinical evidence.

**LL-37**: 100 mcg subcutaneous injection, 3× per week. Dosing extrapolated from preclinical models — no established human therapeutic protocol. Used for periods of increased infectious risk or active immune challenge. Duration: 2–4 weeks as needed.

**KPV**: 200–500 mcg subcutaneous or oral, daily. The anti-inflammatory component — reduces NF-κB-driven inflammation that can impair immune function. Oral KPV targets intestinal mucosal immunity specifically. Duration: 4–8 weeks.

**Timing**: Thymosin Alpha-1 provides the sustained adaptive immune foundation. LL-37 adds acute antimicrobial support during high-risk periods. KPV modulates inflammatory tone that can suppress effective immune responses.

Safety Notes

This stack combines three research peptides with distinct mechanisms. While each has individual safety data (Thymosin Alpha-1 has the most extensive clinical safety profile), the combination has not been studied. Immune-modulating peptides should be approached with particular caution in individuals with autoimmune conditions, active malignancies, or immunosuppressive therapy — modulating immune function in these contexts can have unpredictable consequences. This is not a substitute for vaccination, appropriate antibiotic therapy, or medical evaluation of recurrent infections.

Recommended Products (4)

Frequently Asked Questions

Is this stack appropriate for general immune support?
This stack is designed for individuals with documented immune dysfunction, recurrent infections, or age-related immunosenescence — not for healthy individuals seeking to 'boost' an already functional immune system. Healthy immune systems don't benefit from exogenous immune modulation and may be disrupted by it. Thymosin Alpha-1 specifically is most rational for elderly adults with documented T-cell decline or immunocompromised individuals.
Can this stack help with autoimmune conditions?
Paradoxically, some components may help: KPV's NF-κB inhibition reduces inflammatory cytokine production, and Thymosin Alpha-1 may promote Treg cells that suppress autoimmune responses. However, LL-37 can activate immune cells in ways that could theoretically worsen autoimmune flares. This stack has not been studied in autoimmune disease and should be approached with extreme caution in that context.
How does this compare to vitamin D, zinc, and other immune supplements?
Nutritional immune support (vitamin D, zinc, vitamin C) provides metabolic cofactors — correcting deficiencies in these nutrients is foundational and should be addressed before considering peptide immune modulation. Peptides act on the adaptive immune system directly (T-cell programming, antimicrobial peptide levels), which is a fundamentally different mechanism. They are not substitutes for nutritional adequacy but rather a separate layer of immune support.

Sources

  1. Tuthill C, et al.. “Thymalfasin: biological properties and clinical applications.” International Immunopharmacology 10: 1243-1248 (2010).

Other peptide Ingredient Combinations

Browse All peptide Products

Search

Search across products, blog posts, wiki articles, and more.